Lymphoma research, measles response and medical-product manufacturing.
AbbVie and Genmab reported positive topline Phase 3 results for epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The improvement in progression-free survival could support earlier use of bispecific antibodies, subject to full data review and regulatory assessment.
Read AbbVie announcement →New York declared a statewide disaster emergency after reporting 108 measles cases this year. Expanded vaccination and diagnostic authority highlights the importance of immunization coverage, coordinated surveillance and community communication.
Read at Reuters →Reuters reported a presidential announcement that BD would invest $3 billion in US medical-product manufacturing, including more than $1 billion in Nebraska. The announcement points to supply-chain resilience, but BD had not independently commented when the report was published.
Read at Reuters →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.